King's College London

Research portal

European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II

Research output: Contribution to journalArticlepeer-review

E. Schmidt, H. Rashid, A. V. Marzano, A. Lamberts, G. Di Zenzo, G. F.H. Diercks, S. Alberti-Violetti, R. J. Barry, L. Borradori, M. Caproni, B. Carey, M. Carrozzo, G. Cianchini, A. Corrà, F. G. Dikkers, C. Feliciani, G. Geerling, G. Genovese, M. Hertl, P. Joly & 15 more J. M. Meijer, V. Mercadante, D. F. Murrell, M. Ormond, H. H. Pas, A. Patsatsi, S. Rauz, B. D. van Rhijn, M. Roth, J. Setterfield, D. Zillikens, C.Prost, G. Zambruno, B. Horváth, F. Caux

Original languageEnglish
Pages (from-to)1926-1948
Number of pages23
JournalJournal of the European Academy of Dermatology and Venereology
Volume35
Issue number10
DOIs
Accepted/In press2021
PublishedOct 2021

Bibliographical note

Funding Information: M. Carrozzo received a grant from AFYX. F. Caux has been advisor, speaker or investigator for Principia Biopharma, Roche Laboratories, Pierre Fabre Dermatologie, LEO, Abbvie and Novartis. G. Geerling has been advisor, speaker or investigator for, and received grants from, Dompé, Chiesi, Novartis, Alcon, Allergan, Santen, Oculus, Tearlab, Tearscience, Theapharma and Visumed. B. Horvath has been advisor, speaker or investigator for, and received grants from, Abbvie, Janssen‐Cilag, Solenne B.V, Amgen, Akari Pharmaceutics, Roche, Novartis, UCB Pharma. P. Joly has been consultant for Roche, Amgen, Principia Biopharma, Argenx, AstraZeneca, Regeneron and Thermofisher. D.F. Murrell has been consultant, investigator or speaker for Abbvie, Argenx, AstraZeneca, Dermira, Janssen, Lilly, Novartis, Principia Biopharma, Regeneron, Sanofi and UCB. A. Patsatsi has been advisor, speaker or investigator for Abbvie, Jannsen‐Cilag, Lilly, Novartis, LEO, UCB, Principia Biopharma, L’Oreal and Genesis Pharma. M. Roth has been speaker for Theapharma and Bayer. E. Schmidt has been consultant for, and received grants and honoraria from, UCB, Biotest, Incyte, Euroimmun, Novartis, ArgenX, AstraZeneca, Fresenius Medical Care, Dompe, Synthon/byondis, Admirx, Topas, Thermo Fisher and Roche. G. Zambruno has been consultant for Argenx. D. Zillikens has been consultant, speaker or investigator for Euroimmun, Almirall, UCB, ArgenX, Biotest, Fresenius, Miltenyi, Roche, Biogen, Abbvie and Janssen. Publisher Copyright: © 2021 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

King's Authors

Abstract

This guideline has been initiated by the task force Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology, including physicians from all relevant disciplines and patient organizations. It is a S3 consensus-based guideline that systematically reviewed the literature on mucous membrane pemphigoid (MMP) in the MEDLINE and EMBASE databases until June 2019, with no limitations on language. While the first part of this guideline addressed methodology, as well as epidemiology, terminology, aetiology, clinical presentation and outcome measures in MMP, the second part presents the diagnostics and management of MMP. MMP should be suspected in cases with predominant mucosal lesions. Direct immunofluorescence microscopy to detect tissue-bound IgG, IgA and/or complement C3, combined with serological testing for circulating autoantibodies are recommended. In most patients, serum autoantibodies are present only in low levels and in variable proportions, depending on the clinical sites involved. Circulating autoantibodies are determined by indirect IF assays using tissue substrates, or ELISA using different recombinant forms of the target antigens or immunoblotting using different substrates. The major target antigen in MMP is type XVII collagen (BP180), although in 10–25% of patients laminin 332 is recognized. In 25–30% of MMP patients with anti-laminin 332 reactivity, malignancies have been associated. As first-line treatment of mild/moderate MMP, dapsone, methotrexate or tetracyclines and/or topical corticosteroids are recommended. For severe MMP, dapsone and oral or intravenous cyclophosphamide and/or oral corticosteroids are recommended as first-line regimens. Additional recommendations are given, tailored to treatment of single-site MMP such as oral, ocular, laryngeal, oesophageal and genital MMP, as well as the diagnosis of ocular MMP. Treatment recommendations are limited by the complete lack of high-quality randomized controlled trials.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454